A Study of RVT-1401 in Myasthenia Gravis (MG) Patients
Status:
Completed
Trial end date:
2020-12-21
Target enrollment:
Participant gender:
Summary
The purpose of the current study is to assess safety/tolerability and key pharmacodynamic
(PD) effects that are considered to be associated with clinical benefit (reduction of total
IgG and anti-AChR-IgG) in Myasthenia Gravis patients following treatment with RVT-1401 (also
known as IMVT-1401) compared to placebo.